{"id":"ad26-zebov-2-10-10-vp","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This vaccine uses a non-replicating adenoviral vector to deliver genetic instructions for producing the Ebola virus surface glycoprotein, triggering both cellular and humoral immune responses. The Ad26 vector is designed to be immunogenic while unable to replicate, making it a safe platform for vaccine delivery. It is typically used as a prime in heterologous prime-boost vaccination regimens against Ebola virus disease.","oneSentence":"Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:59:29.280Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ebola virus disease prevention"},{"name":"Post-exposure prophylaxis for Ebola virus exposure"}]},"trialDetails":[{"nctId":"NCT02543268","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-09-21","conditions":"Healthy","enrollment":329},{"nctId":"NCT04228783","phase":"PHASE3","title":"A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-02-18","conditions":"Ebola","enrollment":974},{"nctId":"NCT03929757","phase":"PHASE2","title":"A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2019-08-19","conditions":"Ebola Virus Disease","enrollment":108},{"nctId":"NCT02543567","phase":"PHASE3","title":"A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-09-21","conditions":"Healthy","enrollment":525},{"nctId":"NCT05284097","phase":"PHASE2","title":"Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-09-19","conditions":"Virus Diseases, Hemorrhagic Fever, Ebola, Infections","enrollment":133},{"nctId":"NCT02598388","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-12-10","conditions":"Hemorrhagic Fever, Ebola","enrollment":578},{"nctId":"NCT04556526","phase":"PHASE3","title":"A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-10-05","conditions":"Healthy","enrollment":4031},{"nctId":"NCT04186000","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2019-12-18","conditions":"Ebola Virus Disease","enrollment":699},{"nctId":"NCT02509494","phase":"PHASE3","title":"Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-09-30","conditions":"Ebola Virus Disease","enrollment":1023},{"nctId":"NCT02564523","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-11-06","conditions":"Hemorrhagic Fever, Ebola","enrollment":1075},{"nctId":"NCT04152486","phase":"PHASE3","title":"Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-11-14","conditions":"Ebola Virus Disease","enrollment":20426},{"nctId":"NCT02495246","phase":"PHASE1","title":"A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-09-21","conditions":"Ebola Virus Disease","enrollment":32},{"nctId":"NCT02860650","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-08","conditions":"Healthy","enrollment":72},{"nctId":"NCT02325050","phase":"PHASE1","title":"A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-01-08","conditions":"Healthy","enrollment":164},{"nctId":"NCT02376426","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-03","conditions":"Healthy","enrollment":72},{"nctId":"NCT02376400","phase":"PHASE1","title":"A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-04","conditions":"Healthy","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ad26.ZEBOV 2*10^10 (vp)","genericName":"Ad26.ZEBOV 2*10^10 (vp)","companyName":"Janssen Vaccines & Prevention B.V.","companyId":"janssen-vaccines-prevention-b-v","modality":"Biologic","firstApprovalDate":"","aiSummary":"Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus. Used for Ebola virus disease prevention, Post-exposure prophylaxis for Ebola virus exposure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}